REG - RTW Biotech Opp. - Transaction in Own Shares

RTW Biotech OpportunitiesAnnouncement

25/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250425:nRSY1155Ga&default-theme=true

RNS Number : 1155G  RTW Biotech Opportunities Ltd  25 April 2025

LEI: 549300Q7EXQQH6KF7Z84

25 April 2025

RTW Biotech Opportunities Ltd
(the "Company")

Transaction in Own Shares

The Company announces that on 24 April 2025 it bought back 150,000 of its
Ordinary Shares at a price $1.18 per Ordinary Share.

The repurchased Ordinary Shares will be held by the Company in treasury.
Following the purchase and settlement of these Ordinary Shares, the Company's
issued Ordinary Share capital is 345,967,440 of which 12,353,791 Ordinary
Shares will be held in treasury, which attract no voting rights. Therefore,
the total voting rights in the Company will be 333,613,649.

The Company has bought back these Ordinary Shares under the authority granted
by shareholders at its Annual General Meeting in May 2024, which permits the
Company to repurchase a maximum of 14.99% of its Ordinary Shares. The actual
number of Ordinary Shares repurchased by the Company will depend on market
conditions. This authority lasts until the next shareholder authority granted
(expected to be at the Annual General Meeting in 2025), or until expressly
revoked by shareholders.

The above figure of 333,613,649 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.

No maximum consideration payable has been determined by the Company, but the
Company is unable to pay a price for any Ordinary Shares pursuant to the
buyback which would equate to a premium to the net asset value. It is the
Company's current intention to hold any Ordinary Shares bought back in
treasury.

The Company has instructed Deutsche Numis as its broker in respect of its
buyback transactions. This arrangement is in accordance with the FCA Listing
Rules and the Company's general authority to repurchase shares.

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSUSSVRVBUSUAR